Characterising A Newly Identified Mechanism Causing Elevation Of Intracranial Pressure After Acute Neurological Injury
Funder
National Health and Medical Research Council
Funding Amount
$510,905.00
Summary
Our group discovered that increased pressure on the brain (intracranial pressure – ICP) may be more common and important than has been recognised following stroke, and potentially other brain disorders. We also identified a simple potential therapy, short-duration body cooling, which completely prevents the pressure rise. In this project we will characterise the ICP rise, identify its molecular trigger and determine the best method of body cooling tor use in clinical trials in stroke patients.
Clarifying The Pathogenic Role Of Arousal-hyperventilation In Obstructive And Central Sleep Apnoea: Testing Fundamental Pathophysiological Mechanisms And A Strategic New Treatment
Funder
National Health and Medical Research Council
Funding Amount
$414,717.00
Summary
This project is designed to understand the mechanisms underpinning much more stable breathing during deep sleep in obstructive sleep apnoea (OSA). A newly developed analytical technique will be used to examine breathing effort changes across sleep, and interactions with respiratory-induced awakenings in OSA patients. In addition, a new treatment designed to stabilise breathing will be tested and refined towards a new treatment option for OSA and for central sleep apnoea.
Advanced Imaging To Define Hepatic & Intestinal Drug Disposition In Aging & Liver Diseases
Funder
National Health and Medical Research Council
Funding Amount
$762,123.00
Summary
Aged people and liver disease patients have impaired drug absorption and elimination functions. Their response to drugs varies widely when given drug dosage regimens recommended for normal patients. This project will explore the possibility of using in vivo imaging techniques to define the gut and liver function and their response to administered drugs. This grant will help the selection of appropriate drugs and doses for aged people and patients with liver diseases, i.e. personalised medicine.